A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 [EXTENSION OF 700009915]
Latest Information Update: 18 Jul 2023
At a glance
- Drugs AS04A (Primary) ; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis A vaccine
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GSK
- 21 Feb 2013 New trial record